SCYNEXIS (SCYX) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Annual meeting scheduled for June 25, 2025, to be held virtually, with voting on director elections, auditor ratification, and executive compensation approval.
Proxy materials are available online, and shareholders can vote via internet, phone, or mail until June 24, 2025.
Board recommends voting FOR all director nominees, auditor ratification, and executive compensation proposals.
Voting matters and shareholder proposals
Shareholders will vote on electing seven directors, ratifying Deloitte & Touche LLP as auditor for 2025, and an advisory say-on-pay vote for executive compensation.
Shareholder proposals for the 2026 meeting must be submitted by December 30, 2025, for inclusion in proxy materials.
Universal proxy rules require notice of director nominations by April 26, 2026.
Board of directors and corporate governance
Seven director nominees, including CEO David Angulo, are up for election to serve until the 2026 annual meeting.
43% of directors are women or racially/ethnically diverse.
All directors except the CEO are independent per Nasdaq standards.
Board committees: Audit, Compensation, and Nominating & Corporate Governance, all with independent members.
Chairman and CEO roles are separated to reinforce board independence.
Latest events from SCYNEXIS
- SCY-247 advances as a potent antifungal with strong clinical data and significant market potential.SCYX
investor presentation4 Mar 2026 - 2025 revenue rose sharply on GSK deals; SCY-247 clinical progress and cash runway extended.SCYX
Q4 20254 Mar 2026 - Advancing next-gen antifungal SCY-247 and expanding GSK partnership, with strong financials.SCYX
H.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026 - Virtual annual meeting to vote on directors, auditor, and executive pay set for June 25, 2025.SCYX
Proxy Filing2 Dec 2025 - Secured $24.8M from GSK, advanced SCY-247, and extended cash runway beyond two years.SCYX
Q3 20256 Nov 2025 - Q2 net loss narrowed, cash runway extended, but GSK dispute and Nasdaq risk persist.SCYX
Q2 202514 Aug 2025 - Q3 2024 saw a net loss, no product sales, and ongoing clinical hold, with $84.9M in liquidity.SCYX
Q3 202413 Jun 2025 - Q2 net loss of $14.5M, no product sales, $10M milestone expected, cash at $83.7M.SCYX
Q2 202413 Jun 2025 - Q1 2025 saw a $5.4M net loss, GSK dispute, and China approval for ibrexafungerp.SCYX
Q1 20256 Jun 2025